- Home
- HFRO vs IMAB Comparison
HFRO vs IMAB Comparison
Compare HFRO & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- IMAB
- Stock Information
- Founded
- HFRO 2000
- IMAB 2014
- Country
- HFRO United States
- IMAB United States
- Employees
- HFRO N/A
- IMAB N/A
- Industry
- HFRO Finance/Investors Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- HFRO Finance
- IMAB Health Care
- Exchange
- HFRO Nasdaq
- IMAB Nasdaq
- Market Cap
- HFRO 340.3M
- IMAB 384.6M
- IPO Year
- HFRO N/A
- IMAB 2020
- Fundamental
- Price
- HFRO $6.53
- IMAB $3.62
- Analyst Decision
- HFRO
- IMAB Strong Buy
- Analyst Count
- HFRO 0
- IMAB 5
- Target Price
- HFRO N/A
- IMAB $6.80
- AVG Volume (30 Days)
- HFRO 179.8K
- IMAB 1.8M
- Earning Date
- HFRO 01-01-0001
- IMAB 11-02-2025
- Dividend Yield
- HFRO 8.87%
- IMAB N/A
- EPS Growth
- HFRO N/A
- IMAB N/A
- EPS
- HFRO N/A
- IMAB N/A
- Revenue
- HFRO N/A
- IMAB N/A
- Revenue This Year
- HFRO N/A
- IMAB N/A
- Revenue Next Year
- HFRO N/A
- IMAB N/A
- P/E Ratio
- HFRO N/A
- IMAB N/A
- Revenue Growth
- HFRO N/A
- IMAB N/A
- 52 Week Low
- HFRO $4.24
- IMAB $0.60
- 52 Week High
- HFRO $6.45
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- HFRO 84.60
- IMAB 44.27
- Support Level
- HFRO $6.10
- IMAB $3.20
- Resistance Level
- HFRO $6.23
- IMAB $4.64
- Average True Range (ATR)
- HFRO 0.08
- IMAB 0.43
- MACD
- HFRO 0.01
- IMAB -0.17
- Stochastic Oscillator
- HFRO 100.00
- IMAB 20.49
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).